NASDAQ:AXDX - Accelerate Diagnostics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $18.26 +0.01 (+0.05 %) (As of 04/24/2019 04:41 AM ET)Previous Close$18.25Today's Range$18.01 - $18.3652-Week Range$10.23 - $25.15Volume144,421 shsAverage Volume325,738 shsMarket Capitalization$1.03 billionP/E RatioN/ADividend YieldN/ABeta3.17 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona. Receive AXDX News and Ratings via Email Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXDX Previous Symbol CUSIPN/A CIK727207 Webwww.acceleratediagnostics.com Phone520-365-3100Debt Debt-to-Equity Ratio2.09 Current Ratio22.88 Quick Ratio21.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.67 million Price / Sales181.32 Cash FlowN/A Price / Cash FlowN/A Book Value$1.06 per share Price / Book17.23Profitability EPS (Most Recent Fiscal Year)($1.62) Net Income$-88,330,000.00 Net Margins-1,564.01% Return on Equity-105.12% Return on Assets-43.23%Miscellaneous Employees287 Outstanding Shares56,304,000Market Cap$1.03 billion Next Earnings Date5/8/2019 (Estimated) OptionableOptionable Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions What is Accelerate Diagnostics' stock symbol? Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX." How were Accelerate Diagnostics' earnings last quarter? Accelerate Diagnostics Inc (NASDAQ:AXDX) announced its quarterly earnings data on Tuesday, February, 19th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.41). The medical research company earned $1.80 million during the quarter, compared to analysts' expectations of $1.83 million. Accelerate Diagnostics had a negative net margin of 1,564.01% and a negative return on equity of 105.12%. View Accelerate Diagnostics' Earnings History. When is Accelerate Diagnostics' next earnings date? Accelerate Diagnostics is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Accelerate Diagnostics. What price target have analysts set for AXDX? 3 analysts have issued 1-year target prices for Accelerate Diagnostics' stock. Their forecasts range from $16.00 to $25.00. On average, they anticipate Accelerate Diagnostics' stock price to reach $21.00 in the next year. This suggests a possible upside of 15.0% from the stock's current price. View Analyst Price Targets for Accelerate Diagnostics. What is the consensus analysts' recommendation for Accelerate Diagnostics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accelerate Diagnostics. Has Accelerate Diagnostics been receiving favorable news coverage? Press coverage about AXDX stock has been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. Who are some of Accelerate Diagnostics' key competitors? Some companies that are related to Accelerate Diagnostics include Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Quanterix (QTRX), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Precipio (PRPO), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO), PositiveID (PSID) and Arrayit (ARYC). What other stocks do shareholders of Accelerate Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), BIOLASE (BIOL), Alibaba Group (BABA), ABIOMED (ABMD), Gilead Sciences (GILD), Micron Technology (MU) and Vuzix (VUZI). Who are Accelerate Diagnostics' key executives? Accelerate Diagnostics' management team includes the folowing people: Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)Mr. Steve Reichling, Chief Financial Officer (Age 41)Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)Mr. Kurt Reinhardt, Head of OperationsDr. Romney M. Humphries, Chief Scientific Officer (Age 38) Who are Accelerate Diagnostics' major shareholders? Accelerate Diagnostics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Chicago Capital LLC (0.88%), Trellus Management Company LLC (0.14%) and Reilly Financial Advisors LLC (0.00%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Lawrence Mehren, Steven Reichling and Thomas D Brown. View Institutional Ownership Trends for Accelerate Diagnostics. Which institutional investors are selling Accelerate Diagnostics stock? AXDX stock was sold by a variety of institutional investors in the last quarter, including Trellus Management Company LLC. View Insider Buying and Selling for Accelerate Diagnostics. Which institutional investors are buying Accelerate Diagnostics stock? AXDX stock was acquired by a variety of institutional investors in the last quarter, including Chicago Capital LLC and Reilly Financial Advisors LLC. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Insider Buying and Selling for Accelerate Diagnostics. How do I buy shares of Accelerate Diagnostics? Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Accelerate Diagnostics' stock price today? One share of AXDX stock can currently be purchased for approximately $18.26. How big of a company is Accelerate Diagnostics? Accelerate Diagnostics has a market capitalization of $1.03 billion and generates $5.67 million in revenue each year. The medical research company earns $-88,330,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe. What is Accelerate Diagnostics' official website? The official website for Accelerate Diagnostics is http://www.acceleratediagnostics.com. How can I contact Accelerate Diagnostics? Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected] MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 212 (Vote Outperform)Underperform Votes: 224 (Vote Underperform)Total Votes: 436MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe AXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/24/2019 by MarketBeat.com StaffFeatured Article: What is the downside to momentum investing?